Vyome Holdings, Inc. · NASDAQ:HIND
Vyome — ReShape Lifesciences — Merger or Acquisition (December 2024)
15 slides from Vyome's merger presentation, Dec 11, 2024
Slide 1: Vyome: A US-India healthcare platform with clinical-stage immuno-inflammation assets
Vyome A US-India healthcare platform with clinical-stage immuno-inflammation assets PENDING MERGER $RSLS TO $HIND CORPORATE PRESENTATION DECEMBER 2024
Slide 2: Forward-looking statements
VYOME THERAPEUTICS, INC. (“Vyome”) Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “belie
Slide 3: Vyome is building a 3-pillared healthcare platform in the US-India innovation corridor
Vyome is building a 3-pillared healthcare platform in the US-India innovation corridor ..We intend to list on Nasdaq via reverse merger with $RSLS under the ticker $HIND We have invested nearly a decade and millions of dollars to build a set of immuno-inflammatory assets with several 12-24 month cat
Slide 4: Transforming healthcare leveraging the US-India innovation corridor
At Vyome, we are passionate about transforming healthcare based on world-class science & talent leveraging the US-India innovation corridor Pharma Medical devices AI in healthcare VYOME ($RSLS -> $HIND) US INDIA 4 Vyome has a 3-pillar plan and it intends to build, acquire, or partner with assets in
Slide 5: Why invest in Vyome?
1 2 3 Lower-risk biotech assets with significant catalysts in the next 12-24 months Compelling valuation based on comparable transactions; no debt Powerful US-India value capture opportunity at the optimal time • Vyome has been developing Indian research talent for a decade • US-India relationship e
Slide 6: US-India special relationship unlocks capital markets and innovation opportunity
US-India special relationship and our positioning unlocks significant capital markets and innovation opportunity Ambassador Frank Wisner Former US Ambassador to India & Vyome Board Member to-be Act on emerging health tech opportunities through deal-making Create cost arbitrage opportunities for capi
Slide 7: Current biotech assets offer a low-risk way to unlock significant value
The current biotech assets offer a low-risk way to unlock significant value over the next 12-24 months Malignant Fungating Wound Uveitis (steroid replacement) Inflammatory acne* $2.5B1 Market size $6M Capital required 2027 Potential value inflection timeline $2.6B2 $3M $6.0B3 - (pivotal data) by 203
Slide 8: What is MFW?
What is MFW? MFW is a non-healing wound that occurs when cancer breaks through the skin, causing infection and inflammation. Patients suffer from extreme odor, pain, low self-esteem, and social isolation. MFW afflicts ~10%* of terminal cancer patients & generates a strong odor that dramatically impa
Slide 9: Vyome's biotech asset areas form a pipeline addressing large unmet markets
Vyome’s 2 biotech asset areas form a pipeline addressing large unmet markets Use an unmet orphan indication for low-risk and cost-efficient development to open larger opportunities Our strategy Pivotal studies in 2024 MFW A DNA Gyr/MD2-TLR inhibitor Potential FDA filing for MFW in 2027 Topical infla
Slide 10: Multiple value inflection points over the next 12-24 months
Vyome is focused on unlocking multiple value inflection points from its core pharma assets over the next 12-24 months MFW Program (anticipated milestones) Uveitis Program (anticipated milestones) Q1 2025 Q2/Q3 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026 IIT study interim read outs Appointment of CRO for pi
Slide 11: Compelling entry valuation, no debt, and appealing narrative
Vyome has a compelling entry valuation, no debt, and a narrative appealing to several types of investors merger valuation $120M market comparables valuation $400M+ debt $0M Themes investors allocate 4 Healthcare India Innovation Global macro 11
Slide 12: Market capitalization comparables
Notes: Stage / Phase, Modality, and Market Size refer to that of the Company’s Lead Program / Platform. 1) Vyome market capitalization is based on the implied value attributed to the Company in the reverse merger process. Additional sources: Company websites, press releases, presentations, reports,
Slide 13: Comparable acquisition transactions
Notes: 1) Represents the market capitalizations on the trading day before it was announced that each respective company was to be acquired, unless otherwise noted. 2) Vyome market capitalization is based on the implied value attributed to the Company in the reverse merger process. 3) Landos Biopharm
Slide 14: Vyome has an ideal team to execute its plan
Vyome has an ideal team to execute its plan Deep expertise in building and scaling companies; scientific thought leaders in drug development; extensive US-India crossborder experience Dr. S Sengupta,Ph.D Venkat Nelabhotla Krishna Gupta Mohanjit Jolly Co-Founder CEO & Co-Founder Chairman Board Member
Slide 15: Disclaimer
Disclaimer This Presentation has been provided to you by Chardan Capital Markets, LLC ( “Chardan”) and may not be used or relied upon for any purpose without the written consent of Chardan. The information contained herein (the “Information”) is confidential. By accepting this Information, you agree
ReShape Lifesciences — Merger or Acquisition (December 2024) on 6ix